The organization Vitract.com recently referenced Jona Health during a conference call, noting that Jona’s platform reportedly incorporates approximately 200,000 studies. This claim prompted closer examination, particularly regarding how such figures are defined and communicated.
Public-facing descriptions of Jona’s methodology indicate that its system has “read” approximately 220,000 peer-reviewed studies, with an ongoing ingestion rate of roughly 2,000 new studies per month as microbiome research evolves. However, the distinction between studies that are “read” versus those that are critically evaluated and actively utilized is nontrivial. The use of the term “read” appears to function as a marketing construct, potentially conflating exposure to literature with meaningful incorporation into a validated analytical framework.
For comparative purposes, equivalent metrics from the Microbiome Prescription database demonstrate substantially greater scale and curation rigor. The system has processed a total of 2,953,169 studies—an order of magnitude greater than the figures cited above. Recent weekly ingestion rates further illustrate this difference:
- May 29, 2026: 5,871 new studies
- May 22, 2026: 4,984 new studies
- May 15, 2026: 5,584 new studies
- May 8, 2026: 5,582 new studies
Importantly, each study undergoes manual review prior to inclusion, reflecting the inherent complexity and nuance of microbiome literature that cannot be reliably interpreted through automated methods alone.
More critical than raw ingestion counts is the subset of studies that yield actionable, high-quality data. Within the Microbiome Prescription system, 21,391 studies have been identified as containing usable information and are actively incorporated into the knowledge base. These curated studies underpin approximately 14,518,553 PubMed-derived data points within the expert system. In addition, the platform includes approximately 71,000 experimentally derived bacterial interaction data points sourced from raw datasets.
These distinctions underscore the importance of evaluating not only the quantity of literature processed but also the depth of curation and the proportion of data that is methodologically sound and practically usable.
In conclusion, numerical claims regarding literature scale should be interpreted with caution, particularly when used in marketing contexts. The critical question is not how many studies are nominally “read,” but rather how many are rigorously evaluated and meaningfully integrated into a reliable analytical framework. Microbiome Prescription operates as a not-for-profit, citizen science initiative with the explicit goal of advancing microbiome-informed decision-making through careful curation and transparent methodology, rather than promotional positioning.
Bottom Line
As with all things marketing “Where’s the beef?” and not the hype. Microbiome Prescription is a not profit seeking citizen science endeavor seeking to improve the use of the microbiome.
